Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3000294 | 0.94 | FAAH (0.47) | MEN1KMT2AFAAHMAPTALDH1A1 | |
| SCHEMBL3004867 | 0.93 | MEN1 (0.53) | MEN1KMT2AFAAHMAPTALDH1A1 | |
| SCHEMBL3005706 | 0.91 | MEN1 (0.46) | MEN1KMT2AFAAHMAPTALDH1A1 | |
| SCHEMBL4098737 | 0.90 | L3MBTL1 (0.41) | MEN1KMT2AFAAHMTORMAPT | |
| SCHEMBL3000386 | 0.90 | FAAH (0.56) | MEN1KMT2AFAAHMAPTNLRP3 | |
| SCHEMBL3010325 | 0.90 | MAPT (0.49) | MEN1KMT2AFAAHMAPTALDH1A1 | |
| SCHEMBL2996357 | 0.90 | MAPT (0.47) | FAAHMAPT | |
| SCHEMBL2998909 | 0.88 | PDE4A (0.47) | MEN1KMT2AFAAH | |
| SCHEMBL2994830 | 0.88 | FAAH (0.50) | MEN1KMT2AFAAHMAPTALDH1A1 | |
| SCHEMBL4090405 | 0.88 | MEN1 (0.48) | MEN1KMT2AFAAHMTORMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2610244-A1 | Indole compounds | Ironwood Pharmaceuticals, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| CN-102850324-A | Indole compounds | MICROBIA INC | 2013-01-02 | — | — | CN | disclosed |
| US-20090118503-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| EP-2049520-A2 | INDOLE COMPOUNDS | Ironwood Pharmaceuticals, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008019357-A2 | INDOLE COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118503-A1 | FAAH INHIBITORS | FAAH, FAAH2, CNR2 | MEN1 4573/4885KMT2A 2103/4885FAAH 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.